Skip to main content

LetibotulinumtoxinA Disease Interactions

There are 3 disease interactions with letibotulinumtoxinA.

Major

Botulinum toxin products (applies to letibotulinumtoxinA) dysphagia/respiratory/neuromuscular disorders

Major Potential Hazard, Moderate plausibility. Applicable conditions: Myasthenia Gravis, Pulmonary Impairment

Treatment with botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, daxibotulinumtoxinA, letibotulinumtoxinA and others can result in swallowing and breathing difficulties and in general increased neuromuscular compromise. Deaths due to severe dysphagia or respiratory failure have been reported after treatment with botulinum toxin. Care should be exercised with using these products in patients with pre- existing swallowing or respiratory disorders or peripheral motor neuropathic diseases or neuromuscular disorders (e.g., myasthenia gravis, amyotrophic lateral sclerosis), as they may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia and respiratory compromise. Patients treated with botulinum toxin may require immediate medical attention should they develop these complications. Caution is advised.

Switch to professional interaction data

Major

Botulinum toxin products (applies to letibotulinumtoxinA) infection

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, letibotulinumtoxinA, and others should not be used in the presence of infection at the proposed injection site(s) as it could lead to severe local or disseminated infection(s).

Switch to professional interaction data

Moderate

LetibotulinumtoxinA (applies to letibotulinumtoxinA) cardiovascular disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: History - Myocardial Infarction

Use caution when administering letibotulinumtoxinA to patients with preexisting cardiovascular conditions. Adverse cardiovascular outcomes (some fatal), including arrhythmia and myocardial infarction, have been reported following administration of botulinum toxin products. In some cases, patients had risk factors including preexisting-existing cardiovascular disease.

Switch to professional interaction data

LetibotulinumtoxinA drug interactions

There are 119 drug interactions with letibotulinumtoxinA.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.